drugset / Trial / NCT00943618
Combining Varenicline and Bupropion for Smoking Cessation
Phase 3
Completed
641 enrolled
M.D. Anderson Cancer Center
National Institute on Drug Abuse (NIDA) · collabNational Institutes of Health (NIH) · collabPfizer · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The goal of this clinical research study is learn if the combination of Chantix (varenicline) and Zyban (bupropion) is more effective at helping people to quit smoking than varenicline when given alone. Researchers also want to learn if this drug combination can reduce cravings and other negative symptoms of nicotine withdrawal better than varenicline does alone. The safety of this drug combination will also be tested.
Timeline
- Start
- 2010-05-17
- Primary completion
- 2020-05-31
- Completion
- 2021-09-09
Publications
- Results Cinciripini PM, Minnix JA, Green CE, Robinson JD, Engelmann JM, Versace F, Wetter DW, Shete S, Karam-Hage M. An RCT with the combination of varenicline and bupropion for smoking cessation: clinical implications for front line use. Addiction. 2018 Apr 21:10.1111/add.14250. doi: 10.1111/add.14250. Online ahead of print.
- Hartmann-Boyce J, Theodoulou A, Farley A, Hajek P, Lycett D, Jones LL, Kudlek L, Heath L, Hajizadeh A, Schenkels M, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev. 2021 Oct 6;10(10):CD006219. doi: 10.1002/14651858.CD006219.pub4.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bupropion | Small molecule | 150 mg | Oral |
| Comparator | Varenicline | Small molecule | 0.5 mg | Oral |
Indications
No indication recorded.